针对性蛋白质降解中的纳米TAC:智能交付平台和协同治疗范式
Jieying Qian1, Hongtao Duan1, Qingqi Zheng1
1School of Medicine, South China University of Technology, Guangzhou 510006, PR China.
Advanced drug delivery reviews
|February 19, 2026
概括
纳米粒子辅助向蛋白质降解剂 (NanoTACs) 通过使用纳米技术精确消除致病蛋白质,提供了一种新的治疗方法. 这种方法克服了传统药物的局限性,使以前无法治疗的目标能够得到治疗.
科学领域:
- 纳米医学是一种纳米医学.
- 化学生物学 化学生物学
- 精确瘤学 精确瘤学
背景情况:
- 向性蛋白质降解 (TPD) 提供了对病原蛋白质的持久沉默,克服了耐药性,并使得不可抗药点的调制成为可能.
- 现有的TPD平台 (PROTAC,分子) 在生物可用性,毒性和组织选择性方面面临挑战.
- 纳米粒子辅助向蛋白质降解剂 (NanoTACs) 将TPD与纳米技术相结合,以解决这些局限性.
研究的目的:
- 审查NanoTACs的概念基础,设计原则和翻译前景.
- 突出纳米TACs作为下一代的治疗平台.
- 讨论纳米TACs相对于传统的小分子降解剂的优势.
主要方法:
- 为NanoTAC开发提供合理的纳米载体工程.
- 利用纳米技术实现空间精度和可调性.
- 研究纳米TACs调节生物分布,细胞吸收和释放动力学的能力.
- 探索微环境响应性降解机制.
主要成果:
- 纳米TACs克服了低溶解度,快速清除,以及小分子降解剂的不充分的向性.
- 纳米TAC能够对降解过程进行可编程的控制.
- 在疾病模型中,纳米TACs在降解瘤驱动因素,抑制炎症和消除蛋白质聚合物方面表现出有效性.
结论:
- 纳米TACs在向蛋白质降解方面取得了重大进展.
- 这个平台提供了增强的治疗耐用性和选择性.
- 纳米TAC对精确瘤学和治疗各种疾病具有前景.
相关概念视频
Protein Networks
3.7K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.7K
The Proteasome
7.8K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
7.8K
Tagging and Fusion Proteins
6.4K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
6.4K
The Proteasome
1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
Site-Targeted Drug Delivery Systems: Polymeric Carriers
165
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
165


